Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | May 19, 2026 | clinicaltrials |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial | withdrawn | Phase 2 / Phase 3 | 0 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER |
| 1 |
| Dec 16, 2025 |
| clinicaltrials |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | withdrawn | Phase 2 / Phase 3 | 0 | Lantheus Medical ImagingINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | withdrawn | Phase 3 | 0 | National Institute of CancerologíaOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT06795178 | Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer(KATANA E3M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06795191 | Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer(KATANA E6M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT03632798 | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer(ACSCO) | withdrawn | Phase 3 | 0 | Cordgenics, LLCINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial | withdrawn | Phase 3 | 0 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | withdrawn | Phase 3 | 0 | EQRx International, Inc.INDUSTRY | 0 | Nov 3, 2023 | clinicaltrials |
| NCT05771896 | Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC(CARE) | withdrawn | Phase 3 | 0 | GenesisCare USAOTHER | 0 | Sep 14, 2023 | clinicaltrials |
| NCT05098327 | Pioglitazone and Insulin Resistance in ADT | withdrawn | Phase 3 | 0 | State University of New York at BuffaloOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05363644 | BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy | withdrawn | Phase 3 | 0 | AdventHealthOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | withdrawn | Phase 3 | 0 | Agenus Inc.INDUSTRY | 2 | Oct 5, 2022 | clinicaltrials |
| NCT04806945 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | withdrawn | Phase 2 / Phase 3 | 0 | Menoufia UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03905902 | DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma(VITALIA) | withdrawn | Phase 3 | 0 | SOTIO a.s.INDUSTRY | 0 | Dec 23, 2021 | clinicaltrials |
| NCT03800784 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT03806049 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | withdrawn | Phase 3 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 3 | Jul 15, 2021 | clinicaltrials |
| NCT04225299 | Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer | withdrawn | Phase 3 | 0 | Steba Biotech S.A.OTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03488810 | Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer(ARN-509) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Aug 17, 2020 | clinicaltrials |
| NCT00693342 | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Feb 24, 2020 | clinicaltrials |
| NCT03699176 | Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 7) | withdrawn | Phase 3 | 0 | BayerINDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT03298958 | Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer | withdrawn | Phase 3 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT02438852 | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer | withdrawn | Phase 3 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 15, 2018 | clinicaltrials |
| NCT02053311 | Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents | withdrawn | Phase 3 | 0 | Swiss Cancer InstituteOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT02471495 | RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE) | withdrawn | Phase 3 | 0 | Medical Enterprises Europe B.V.INDUSTRY | 0 | May 7, 2018 | clinicaltrials |
| NCT02736435 | Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound | withdrawn | Phase 3 | 0 | Thunder Bay Regional Health Research InstituteOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01762592 | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT | withdrawn | Phase 3 | 0 | Heidelberg Pharma AGINDUSTRY | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Genentech, Inc.INDUSTRY | 0 | Oct 19, 2016 | clinicaltrials |
| NCT00691899 | A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) | withdrawn | Phase 3 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2016 | clinicaltrials |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Dec 31, 2014 | clinicaltrials |
| NCT01284205 | First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC | withdrawn | Phase 3 | 0 | Bioniche Life Sciences Inc.INDUSTRY | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00874302 | Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms | withdrawn | Phase 3 | 0 | Repros Therapeutics Inc.INDUSTRY | 2 | Jun 27, 2014 | clinicaltrials |
| NCT00922129 | Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00043212 | Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective. | withdrawn | Phase 3 | 0 | Northwest BiotherapeuticsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00258466 | Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer | withdrawn | Phase 3 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Apr 8, 2013 | clinicaltrials |
| NCT00057928 | S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer | withdrawn | Phase 3 | 0 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 13, 2012 | clinicaltrials |
| NCT00728533 | Open-Label, Randomised Parallel-Group Study | withdrawn | Phase 3 | 0 | Ferring PharmaceuticalsINDUSTRY | 0 | Mar 18, 2011 | clinicaltrials |
Data updated 22 days agoSource updated May 19, 2026source: clinicaltrials